Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7766 in Advanced Solid Tumors or Lymphomas
NCT04144140Phase 1Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2020
- Primary completion
- Jul 2022
- Modality
- Orthosteric Ligands
- Countries
- 5
01
Overview
Phase 1, open-label trial of e7766 in solid tumor (advanced stage) and lymphoma (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Dose-Limiting Toxicities, Treatment-Emergent Adverse Events and 3 more. Started Feb 2020; status: terminated.
02
Drugs
e7766
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT04144140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04144140.